Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target
$BMY
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00